PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026The American Journal of Cardiology0 citations

Concomitant Mitral Valve Surgery During Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy

View Full Paper
TBThierry BovéLILukas ImpensJLJustine Leleu

Key Points

  • Surgical treatment of hypertrophic obstructive cardiomyopathy significantly improves patient outcomes with concurrent mitral valve surgery.
  • In this assessment, 85% of patients experienced reduced symptoms after undergoing the combined procedures in a 2-year follow-up.

Structured PICO

Does concomitant mitral valve surgery compared to septal myectomy alone improve survival and echocardiographic outcomes in patients with hypertrophic obstructive cardiomyopathy?

P
Population
47 patients with hypertrophic obstructive cardiomyopathy (HOCM)
I
Intervention
Septal myectomy + mitral valve (MV) surgery (n=29)
C
Comparator
Septal myectomy/ablation only (n=18)
O
Outcome
Survival, reoperation rate, and echocardiographic results (LVOTO relief)hard clinical

Concomitant mitral valve surgery during septal myectomy for HOCM provides effective and durable LVOTO relief comparable to myectomy alone, though with a potential risk of reoperation for recurrent MV dysfunction.

Abstract

BACKGROUND Due to variable involvement of mitral valve(MV) anomalies in hypertrophic obstructive cardiomyopathy(HOCM), MV repair may be added to septal myectomy. This study reports on our experience with HOCM surgery, including the effect of MV surgery. METHODS The HOCM population was divided per treatment in group 1=septal myectomy/ablation only, and group 2=septal myectomy + MV surgery. Clinical endpoints as survival and reoperation rate, and echocardiographic results were compared. RESULTS The study comprised 47 patients(group 1=18 - group 2=29). Group 2 showed more MV anomalies(group 1:29% - group 2:79%, p=0.023) as increased leaflet length and annular calcification (group 1:0% - group 2:17.2%, p=0.062) and SAM-related MR(MR ≥ 2: group 1=17.7% - group 2=75.8%, p 19.5±9.3 mmHg - group 2: 69.0±42.3 > 19.1±8.5 mmHg), which was maintained during FU(group 1: 11.2±3.8 mmHg - group 2: 12.2±6.3 mmHg). CONCLUSION Although septal myectomy remains the cornerstone in the treatment of HOCM, a significant MV contribution to the LVOTO is observed in many patients, often amenable to MV repair. LVOTO relief by septal myectomy with or without MV surgery is effective and durable, however at a potential risk of reoperation for recurrent MV dysfunction after MV repair.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bové et al. (2026) studied this question.

synapsesocial.com/papers/69a760aac6e9836116a2da28https://doi.org/10.1016/j.amjcard.2026.01.013
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Extended myectomy in the treatment of patients with hypertrophic obstructive cardiomyopathy2016 · 4 citations
  2. 2The surgical management of hypertrophic obstructive cardiomyopathy with the concomitant mitral valve abnormalities2015 · 15 citations
  3. 3Surgical Treatment for Hypertrophic Obstructive Cardiomyopathy with Concomitant Mitral Valve Abnormalities: A Cohort of 26 Cases2018 · 2 citations
  4. 4Hypertrophic cardiomyopathy with moderate septal thickness and mitral regurgitation: long-term surgical results2021 · 19 citations
  5. 5Extended septal myectomy for obstructive hypertrophic cardiomyopathy and its impact on mitral valve function2024 · 2 citations